{"id":"NCT02725593","sponsor":"AstraZeneca","briefTitle":"Study to Evaluate Safety and Efficacy of Dapagliflozin in Patients With Type 2 Diabetes Mellitus Aged 10-24 Years","officialTitle":"A 24 Week, Multicenter, Randomized, Double-Blind, Parallel Group, Phase 3 Trial With a 28 Week Long Term Safety Extension Period Evaluating the Safety and Efficacy of Dapagliflozin 10 mg in T2DM Patients Aged 10-24 Years","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-06-22","primaryCompletion":"2020-04-06","completion":"2020-04-06","firstPosted":"2016-04-01","resultsPosted":"2020-12-02","lastUpdate":"2022-02-23"},"enrollment":72,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Type 2 Diabetes"],"interventions":[{"type":"DRUG","name":"Dapagliflozin","otherNames":["FORXIGA"]},{"type":"DRUG","name":"Dapagliflozin placebo","otherNames":[]}],"arms":[{"label":"Dapagliflozin","type":"EXPERIMENTAL"},{"label":"Dapagliflozin placebo","type":"PLACEBO_COMPARATOR"}],"summary":"A trial of patients aged 10-24 years with type 2 diabetes mellitus to evaluate the comparative efficacy and safety between dapagliflozin and Placebo.","primaryOutcome":{"measure":"Adjusted Change From Baseline in Glycated Haemoglobin (HbA1c) at Week 24","timeFrame":"Baseline to Week 24","effectByArm":[{"arm":"Dapagliflozin 10mg/ Dapagliflozin 10mg","deltaMin":-0.25,"sd":0.3},{"arm":"Placebo/ Dapagliflozin 10mg","deltaMin":0.5,"sd":0.34}],"pValues":[{"comp":"OG000 vs OG001","p":"0.101"}]},"eligibility":{"minAge":"10 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":42,"countries":["United States","Hungary","Israel","Mexico","Romania","Russia","United Kingdom"]},"refs":{"pmids":["35378069"],"seeAlso":["https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D1690C00017&amp;attachmentIdentifier=a9e77cda-496a-4e09-aa87-cbe0538b927b&amp;fileName=D1690C00017_CSP_redacted.pdf&amp;versionIdentifier=","https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D1690C00017&amp;attachmentIdentifier=27e64a31-b91e-45ea-bd34-12f4c16b9806&amp;fileName=D1690C00017_SAP_redacted.pdf&amp;versionIdentifier="]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":39},"commonTop":["Headache","Nasopharyngitis","Vitamin D deficiency","Oropharyngeal pain","Diarrhoea"]}}